- Home
- CGNT vs ACHV Comparison
CGNT vs ACHV Comparison
Compare CGNT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGNT | ACHV |
|---|---|---|
| Founded | 2020 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.9M | 618.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CGNT | ACHV |
|---|---|---|
| Price | $9.37 | $6.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.50 | ★ $14.67 |
| AVG Volume (30 Days) | 476.7K | ★ 1.1M |
| Earning Date | 06-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $10.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.29 | $2.45 |
| 52 Week High | $12.31 | $7.11 |
Technical Indicators
Market Signals| Indicator | CGNT | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 66.41 |
| Support Level | $9.32 | $4.04 |
| Resistance Level | $9.43 | $7.11 |
| Average True Range (ATR) | 0.32 | 0.32 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 89.42 | 93.27 |
Price Performance
Historical ComparisonAbout CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.